StrongDecrease
Apolipoprotein B change
Orforglipron → Apolipoprotein B change
Orforglipron → Apolipoprotein B change
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Orforglipron improves cardiovascular risk markers in diabetes and obesity.
Key finding
Decreases in SBP were observed with orforglipron by -7.3 to -9.4 mmHg.
Orforglipron treatment led to significant reductions in cardiovascular risk markers among participants with type 2 diabetes and obesity.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Extended (5–20+ y)
High bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Orforglipron
Study type
RCTs
Follow-up
Extended (5–20+ y)
Primary outcome
Systolic blood pressure change
Comparator
Dulaglutide treatment, Placebo treatment
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
Orforglipron treatment led to significant reductions in cardiovascular risk markers among participants with type 2 diabetes and obesity.
Clinical relevance
The findings highlight the potential of orforglipron as a therapeutic option for managing cardiovascular risk in patients with type 2 diabetes and obesity. Given the high prevalence of cardiovascular disease in this population, effective interventions are crucial for improving health outcomes and reducing healthcare costs.
Keep in mind
Unclear effectiveness for some outcomes. Limited generalizability due to specific population characteristics. Potential unmeasured confounders affecting results.
Published in
Journal Reference
Publication details and source links for this paper.
Sean W, Julio R, Manige K, et al. Orforglipron treatment was associated with beneficial changes in cardiovascular risk markers in participants with type 2 diabetes and obesity. Cardiovascular Diabetology. 2025;24:240. doi:10.1186/s12933-025-02781-x
Save this study and add notes to your research library.
Main Effects
Systolic blood pressure decreased by -8.4 mmHg (p=0.001).
Diastolic blood pressure decreased by -1.5 mmHg (p=0.05).
LDL cholesterol decreased by -14.3 mg/dL (p=0.001).
Triglycerides decreased by -16.4 mg/dL (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Orforglipron and Apolipoprotein B change, Apolipoprotein C3 change, C-reactive protein, and 5 more.
This study contributes evidence to
Primary intervention
Orforglipron
Primary outcomes
- Apolipoprotein B change
- Apolipoprotein C3 change
- C-reactive protein
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
8
Evidence pairs
28
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Apolipoprotein C3 change
Orforglipron → Apolipoprotein C3 change
Orforglipron → Apolipoprotein C3 change
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
C-reactive protein
Orforglipron → C-reactive protein
Orforglipron → C-reactive protein
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
Diastolic blood pressure
Orforglipron → Diastolic blood pressure
Orforglipron → Diastolic blood pressure
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
Interleukin-6 change
Orforglipron → Interleukin-6 change
Orforglipron → Interleukin-6 change
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
LDL cholesterol
Orforglipron → LDL cholesterol
Orforglipron → LDL cholesterol
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
Systolic blood pressure
Orforglipron → Systolic blood pressure
Orforglipron → Systolic blood pressure
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
Triglycerides
Orforglipron → Triglycerides
Orforglipron → Triglycerides
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Orforglipron reduced systolic blood pressure by 8.4 mmHg.
- LDL cholesterol levels decreased by 14.3 mg/dL.
- Significant reductions in inflammatory markers were observed.
Who this applies to
- Adults with type 2 diabetes.
- Individuals with obesity.
Keep in Mind
- Results may not apply to populations outside the study.
- Further research is needed to confirm long-term effects.
- Effectiveness was unclear for some cardiovascular risk markers.
Between the Lines
- Unclear effectiveness for some outcomes.
- Limited generalizability due to specific population characteristics.
- Potential unmeasured confounders affecting results.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Orforglipron improve apolipoprotein b change?
Emerging Evidence
Orforglipron appears to improve Apolipoprotein B change.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Apolipoprotein B change
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Orforglipron improve apolipoprotein c3 change?
Emerging Evidence
Orforglipron appears to improve Apolipoprotein C3 change.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Apolipoprotein C3 change
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Orforglipron improve c-reactive protein?
Emerging Evidence
Orforglipron appears to improve C-reactive protein.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-reactive protein
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Orforglipron improve diastolic blood pressure?
Emerging Evidence
Orforglipron appears to improve Diastolic blood pressure.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Mediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsMobile health support improves blood glucose levels in type 2 diabetesNatural products may improve glycemic control in type 2 diabetesScalable diabetes education improves care coordinationSmartphone app shows little effect on physical activity in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.